Introduction {#s1}
============

Type 1 diabetes mellitus (T1D) has been previously reported to increase the risk of microvascular complications and cardiovascular disease (CVD) [@pone.0058472-Libby1]--[@pone.0058472-Marcovecchio1]. In contrast to the reduction in cardiovascular mortality within the general US population, the declining trend is less evident in individuals with diabetes [@pone.0058472-Gu1]. Despite improved disease management strategies, CVD remains the primary cause of death in patients with T1D [@pone.0058472-Laing1] and a ten-fold increase in risk is reported in those with diabetic nephropathy (DN) relative to those without it [@pone.0058472-Tuomilehto1]. DN is a complex, multi-factorial disease and identifying robust genetic risk factors has proved challenging. Several risk factors are common to both CVD and DN, including hypertension, male gender, smoking and modifiable dyslipidemia [@pone.0058472-Laing1]--[@pone.0058472-Mulec1].

Dyslipidemia results from abnormal lipid metabolism with departure from optimum vascular cholesterol and triglyceride levels leading to atherosclerosis, a process of fatty acid plaque deposition in arterial blood vessels. Previous studies reported normal low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels in individuals with T1D, with elevated triglyceride levels more commonly associated with poor glycemic control [@pone.0058472-Molitch1]. This abnormal lipid profile can result from insulin deficiency with subsequent reduction in lipoprotein lipase activity and diminished ability for chylomicron and very low-density lipoprotein (VLDL) clearance [@pone.0058472-OBrien1]. This contrasts with individuals with type 2 diabetes (T2D) who often exhibit reduced HDL levels with a shift in LDL to the more atherogenic dense VLDL particles as a consequence of increased hepatic production. This process is increased by insulin resistance resulting in reduced clearance of VLDL and chylomicrons [@pone.0058472-Ginsberg1].

Observational studies have identified multiple lipid abnormalities in both incipient and overt DN [@pone.0058472-Groop1]--[@pone.0058472-Watts1], although this has not been consistently reported [@pone.0058472-Mattock1]. While the exact mechanism of effect is not fully understood, dyslipidemia has been associated with DN progression as well as increasing cardiovascular risk [@pone.0058472-Thomas1]--[@pone.0058472-Tolonen1]. Supporting evidence implicates insulin resistance as pivotal in the development and/or progression of this condition [@pone.0058472-Taskinen1]--[@pone.0058472-Mooradian1]. Potential mechanisms contributing to renal injury in DN have included stimulation of pro-inflammatory and pro-fibrotic cytokine production, cell apoptosis, vasoconstriction and modulation of mesangial cell proliferation [@pone.0058472-Heeringa1]--[@pone.0058472-Nishida1]. As such, parallels between mechanisms that underpin atherosclerosis and glomerulosclerosis provide support for investigation of the parameters that contribute to both conditions [@pone.0058472-Kamanna1].

While previous evidence demonstrates modulation of lipid profiles through lifestyle changes such as smoking, diet and physical activity, recent studies have also identified common genetic variation as regulators of lipid levels and subsequent dyslipidemia [@pone.0058472-Kooner1]--[@pone.0058472-Waterworth1]. To date, almost 100 genetic loci have been reported in association with serum cholesterol and triglyceride levels [@pone.0058472-Tukiainen1]. Aulchenko and colleagues highlighted that many of the loci influencing lipid levels and CVD risk had previously been identified in association studies enriched by participants with diabetes [@pone.0058472-Aulchenko1]. The management of diabetic dyslipidemia, a well-recognized and modifiable risk factor, is a key element in the multifactorial approach to prevent CVD in individuals with diabetes [@pone.0058472-Solano1]. In light of the evidence supporting association of these variants with dyslipidemia in individuals with diabetes, we sought to assess the allelic frequency of 53 common single nucleotide polymorphisms (SNPs) in 37 key loci in individuals with DN using a case-control design involving 1467 individuals with T1D. These loci and SNPs were selected on the basis of their functional significance and previous reported association with dyslipidemia [@pone.0058472-Kooner1]--[@pone.0058472-Waterworth1].

Methods {#s2}
=======

Participants {#s2a}
------------

Research ethics approval was obtained from the South and West Multicentre Research Ethics Committee (MREC/98/6/71) and Queens University Belfast Research Ethics Committee. Written informed consent was obtained prior to participation. All recruited individuals were white, had T1D diagnosed before 32 years of age and were born in the UK or Ireland. Patients (n = 718) and controls (n = 749) originated from the Warren 3/UK Genetics of Kidneys in Diabetes (GoKinD) and all-Ireland collections [@pone.0058472-Kavanagh1]. The definition of DN in cases was based on development of persistent proteinuria (\>0.5 g protein/24 h) at least 10 years after diagnosis of T1D, hypertension (blood pressure \>135/85 mmHg or treatment with antihypertensive agents) and associated diabetic retinopathy. Controls were individuals with T1D for at least 15 years with normal urinary albumin excretion rates and no evidence of microalbuminuria on repeated testing. In addition, control subjects had not been prescribed antihypertensive drug treatment avoiding possible misclassification of diabetic individuals as 'control phenotypes' when the use of antihypertensive treatment may have reduced urinary albumin excretion into the normal range. Individuals with microalbuminuria were excluded from both case and control groups since it was not possible to be confident in assigning case/control status for such individuals whose urinary albumin excretion might either regress or progress over time [@pone.0058472-Perkins1].

SNP selection and genotyping {#s2b}
----------------------------

SNPs (n = 53) were selected on the basis of previously reported association with dyslipidemia [@pone.0058472-Willer1]--[@pone.0058472-Aulchenko1] and of minor allele frequency (MAF) exceeding 0.1 in populations of European descent. Genotyping was performed by MassARRAY iPLEX (Sequenom, San Diego, CA, USA) assays according to the manufacturer\'s instructions. Quality filters for exclusion of SNPs included call rates below 95% and deviation from HWE (*P*\<0.001). DNA samples were excluded if missing genotypes exceeded 10%. Other quality control measures included parent/offspring trio samples, duplicates on plates, random sample allocation to plates, independent scoring of problematic genotypes by two individuals and re-sequencing of selected DNAs to validate genotypes.

Statistical analysis {#s2c}
--------------------

Clinical characteristics of cases and controls were compared using the z-test for large independent samples and the χ^2^ test. Association analyses were performed using PLINK (version 1.07; <http://pngu.mgh.harvard.edu/~purcell/plink/>). Initially a χ^2^ test for trend (1 *df*) was used with stratification by collection center. Logistic regression analysis was performed on each SNP with terms for potential confounders (collection center, gender, duration of T1D and HbA1c) included in the model. A sensitivity analysis to minimize potential misclassification of case/control status was performed by excluding samples from those control individuals with an estimated glomerular filtration (eGFR) \<60 ml/min/1.73 m^2^. The level of statistical significance was set at 5% and adjustment for multiple testing performed by permutation test (n = 100,000). Potential gene-gene interactions between SNPs were assessed using likelihood ratio χ^2^ tests in the logistic regression with terms for potential confounders (collection center, gender, duration of T1D and HbA1c) included in the model.

Results {#s3}
=======

The clinical characteristics of the DN cases (n = 718) and diabetic controls (n = 749) genotyped in this study are listed in [Table 1](#pone-0058472-t001){ref-type="table"}. There were more males, higher mean HbA1c and blood pressure values (despite the use of antihypertensive treatment) in the case group compared with the control group. All comparisons were significant at *P*\<0.001 with the exception of age at diagnosis, LDL cholesterol and body mass index which did not differ significantly between groups. Approximately one quarter of cases (26.9%) had end-stage renal disease (ESRD).

10.1371/journal.pone.0058472.t001

###### Clinical characteristics of diabetic nephropathy (DN) cases and no nephropathy diabetic controls.

![](pone.0058472.t001){#pone-0058472-t001-1}

  Characteristic                                                                                                          DN cases (n = 718)   Controls (n = 749)   P value
  ---------------------------------------------------------------------------------------------------------------------- -------------------- -------------------- ---------
  Male; n (%)                                                                                                                415 (57.8%)          320 (42.7%)       \<0.001
  Age at diagnosis of T1D (yr)                                                                                                 14.8±7.7             15.5±7.9         0.09
  Duration of T1D (yr)[a](#nt102){ref-type="table-fn"}                                                                         33.3±9.4             28.1±9.0        \<0.001
  Age at sampling                                                                                                             48.1±10.4            43.6±11.0        \<0.001
  HbA1c (%)[b](#nt103){ref-type="table-fn"}                                                                                    9.0±1.9              8.6±1.5         \<0.001
  Systolic blood pressure (mmHg)[b](#nt103){ref-type="table-fn"}                                                              144.9±20.9           125.0±14.7       \<0.001
  Diastolic blood pressure (mmHg)[b](#nt103){ref-type="table-fn"}                                                             81.5±11.4             75.4±7.8        \<0.001
  Body mass index (kg/m^2^)                                                                                                    26.3±4.7             26.1±4.2         0.50
  Serum cholesterol (mmol/L)                                                                                                  5.34±1.22            5.09±0.91        \<0.001
  HDL cholesterol (mmol/L)                                                                                                    1.59±0.55            1.78±0.47        \<0.001
  LDL cholesterol (mmol/L)                                                                                                    2.88±0.95            2.80±0.75         0.17
  Serum triglycerides (mmol/L) median (interquartile range)                                                                 1.4 (1.0--2.2)       1.0 (0.7--1.4)     \<0.001
  Serum creatinine (µmol/L);[c](#nt104){ref-type="table-fn"} median (interquartile range)                                   130 (102--183)        92 (79--105)      \<0.001
  Estimated glomerular filtration rate (ml/min/1.73m^2^);[c](#nt104){ref-type="table-fn"} median (interquartile range)       48 (33--66)          70 (59--85)       \<0.001
  End-stage renal disease; n (%)                                                                                             193 (26.9%)               NA             NA
  Passed quality control criteria; n (%)                                                                                     684 (95.3%)          710 (94.8%)        0.68

Unless otherwise stated values are mean ± standard deviation.

Calculated from the dates of diagnosis and recruitment.

Average of the three most recent values prior to recruitment.

Excludes subjects receiving renal replacement therapy (dialysis or transplant).

A total of 53 SNPs were genotyped using MassARRAY iPLEX technology in 718 cases and 749 controls ([Table 2](#pone-0058472-t002){ref-type="table"}). We excluded 73 samples (34 cases and 39 controls) from the analysis with ≥10% missing genotypes. The average call rate for all SNPs analysed was 99.3%. The genotype distribution for each SNP did not deviate significantly from HWE in either cases or controls. No duplicate or Mendelian inconsistencies were observed.

10.1371/journal.pone.0058472.t002

###### Minor allele frequencies (MAF) and genotype counts in 684 diabetic nephropathy cases and 710 no nephropathy diabetic controls.

![](pone.0058472.t002){#pone-0058472-t002-2}

                                                           Genomic       Case         Controls      Confidence                                                                                
  -------------------------------------------- ---- ---- ----------- ------------ ---------------- ------------ ------------- ------ ------------- ------ ------- ------ ------------ ------- --------
  rs10903129                                    34   1    25768937     intronic       *TMEM57*       \[A/G\]     128/319/236   0.42   124/364/220   0.43   0.548   0.92   0.77--1.10   0.368   0.261
  rs11206510                                    33   1    55496039    intergenic      *PCSK9*        \[C/T\]     32/172/461    0.18   25/217/464    0.19   0.431   0.90   0.72--1.12   0.341   0.377
  rs1167998                                     34   1    62931632     intronic       *DOCK7*        \[C/A\]     84/298/298    0.34   83/308/314    0.34   0.719   0.98   0.82--1.18   0.867   0.957
  rs10889353                                    34   1    63118196     intronic       *DOCK7*        \[C/A\]     81/297/305    0.34   80/307/320    0.33   0.748   0.98   0.82--1.18   0.858   0.957
  [1](#nt110){ref-type="table-fn"}rs12740374    32   1    109817590     3′UTR         *CELSR2*       \[T/G\]     33/230/421    0.22   36/219/452    0.21   0.494   1.10   0.89--1.36   0.388   0.520
  rs646776                                      32   1    109818530   intergenic      *CELSR2*       \[G/A\]     33/225/424    0.21   37/219/452    0.21   0.678   1.07   0.86--1.32   0.540   0.707
  rs2144300                                     31   1    230294916    intronic       *GALNT2*       \[C/T\]     105/337/235   0.40   108/330/269   0.39   0.337   1.07   0.89--1.28   0.490   0.573
  rs4846914                                     32   1    230295691    intronic       *GALNT2*       \[G/A\]     109/339/236   0.41   110/332/268   0.39   0.320   1.05   0.88--1.26   0.578   0.620
  rs6754295                                     34   2    21206183    intergenic       *APOB*        \[G/T\]     27/238/416    0.21   39/239/432    0.22   0.573   1.02   0.83--1.27   0.833   0.318
  rs7557067                                     33   2    21208211    intergenic       *APOB*        \[G/A\]     28/241/415    0.22   40/238/432    0.22   0.663   1.03   0.83--1.27   0.800   0.286
  rs673548                                      34   2    21237544     intronic        *APOB*        \[A/G\]     20/228/430    0.20   30/215/454    0.20   0.951   1.07   0.85--1.34   0.564   0.263
  rs1260326                                     33   2    27730940     missense        *GCKR*        \[T/C\]     93/329/258    0.38   114/305/290   0.38   0.879   0.99   0.83--1.19   0.943   0.642
  rs780094                                      34   2    27741237     intronic        *GCKR*        \[A/G\]     86/311/273    0.36   104/296/294   0.36   0.885   0.98   0.82--1.18   0.842   0.798
  rs6756629                                     34   2    44065090     missense       *ABCG5*        \[A/G\]      3/90/591     0.07    4/92/610     0.07   0.947   0.90   0.64--1.27   0.560   0.449
  rs6544713                                     33   2    44073881     intronic       *ABCG8*        \[T/C\]     68/308/307    0.33   86/305/318    0.34   0.525   1.03   0.85--1.24   0.759   0.811
  rs3846662                                     34   5    74651084     intronic       *HMGCR*        \[C/T\]     104/324/246   0.39   113/323/254   0.40   0.866   0.98   0.82--1.17   0.815   0.258
  rs3846663                                     33   5    74655726     intronic       *HMGCR*        \[T/C\]     83/302/297    0.34   92/308/309    0.35   0.831   0.96   0.80--1.16   0.694   0.258
  rs1501908                                     33   5    156398169   intergenic   *TIMD4/HAVCR1*    \[C/G\]     102/313/265   0.38   99/329/279    0.37   0.686   1.10   0.92--1.32   0.288   0.200
  rs12670798                                    34   7    21607352     intronic       *DNAH11*       \[C/T\]     37/255/392    0.24   43/254/413    0.24   0.948   0.99   0.81--1.22   0.945   0.759
  rs2240466                                     34   7    72856269     intronic       *BAZ1B*        \[T/C\]      5/175/503    0.14   14/151/545    0.13   0.463   1.13   0.87--1.47   0.374   0.109
  [2](#nt111){ref-type="table-fn"}rs714052      32   7    72864869     intronic       *BAZ1B*        \[C/T\]      5/173/503    0.13   14/151/543    0.13   0.534   1.12   0.86--1.46   0.396   0.115
  rs7819412                                     33   8    11045161     intronic        *XKR6*        \[G/A\]     168/322/179   0.49   152/361/196   0.47   0.231   1.05   0.88--1.26   0.583   0.420
  rs10096633                                    34   8    19830921    intergenic       *LPL*         \[T/C\]     11/124/548    0.11    8/145/557    0.11   0.584   0.82   0.62--1.08   0.154   0.130
  rs12678919                                    33   8    19844222    intergenic       *LPL*         \[G/A\]      9/97/576     0.08    5/111/593    0.09   0.923   0.84   0.62--1.14   0.265   0.219
  rs2083637                                     34   8    19865175    intergenic       *LPL*         \[C/T\]     50/245/388    0.25   51/271/388    0.26   0.542   0.90   0.74--1.10   0.321   0.191
  rs17321515                                    32   8    126486409   intergenic      *TRIB1*        \[G/A\]     153/343/188   0.47   153/365/191   0.47   0.949   1.03   0.86--1.23   0.717   0.564
  [3](#nt112){ref-type="table-fn"}rs2954029     32   8    126490972   intergenic      *TRIB1*        \[T/A\]     149/333/202   0.46   147/366/197   0.46   0.852   1.02   0.86--1.22   0.797   0.617
  rs471364                                      33   9    15289578     intronic       *TTC39B*       \[G/A\]      6/147/529    0.12   11/144/554    0.12   0.967   1.01   0.77--1.33   0.951   0.807
  rs3905000                                     34   9    107657070    intronic       *ABCA1*        \[A/G\]     11/180/492    0.15   17/179/513    0.15   0.863   1.02   0.80--1.31   0.882   0.810
  rs1883025                                     33   9    107664301    intronic       *ABCA1*        \[A/G\]     51/276/356    0.28   55/316/338    0.30   0.168   0.94   0.78--1.15   0.573   0.620
  rs7395662                                     34   11   48518893    intergenic      *OR4A47*       \[A/G\]     95/326/263    0.38   92/339/279    0.37   0.628   1.08   0.90--1.30   0.415   0.524
  rs174547                                      33   11   61570783     intronic       *FADS1*        \[C/T\]     78/319/287    0.35   70/327/306    0.33   0.402   1.13   0.93--1.37   0.212   0.524
  rs174570                                      34   11   61597212     intronic       *FADS2*        \[T/C\]      8/161/508    0.13   10/168/525    0.13   0.817   1.04   0.79--1.35   0.799   0.527
  rs964184                                      32   11   116648917   intergenic      *ZNF259*       \[G/C\]     10/138/535    0.12   10/162/538    0.13   0.314   0.82   0.63--1.07   0.142   0.172
  rs2338104                                     31   12   109895168    intronic       *KCTD10*       \[C/G\]     149/340/193   0.47   189/329/189   0.50   0.089   0.91   0.76--1.08   0.268   0.172
  rs2650000                                     33   12   121388962   intergenic      *HNF1A*        \[T/G\]     76/292/312    0.33   82/315/307    0.34   0.444   0.88   0.73--1.06   0.180   0.257
  rs4775041                                     31   15   58674695    intergenic       *LIPC*        \[C/G\]     65/288/328    0.31   68/284/356    0.30   0.555   1.05   0.87--1.27   0.596   0.348
  rs10468017                                    33   15   58678512    intergenic       *LIPC*        \[T/C\]     61/290/330    0.30   65/279/366    0.29   0.403   1.07   0.88--1.29   0.502   0.275
  rs1532624                                     34   16   57005479     intronic        *CETP*        \[T/G\]     109/337/233   0.41   149/341/213   0.45   0.015   0.82   0.69--0.99   0.034   0.514
  rs2271293                                     34   16   67902070     intronic       *NUTF2*        \[A/G\]     11/131/521    0.12    8/129/543    0.11   0.470   0.93   0.70--1.25   0.638   0.272
  rs4939883                                     34   18   47167214    intergenic       *LIPG*        \[T/C\]     28/213/437    0.20   26/212/467    0.19   0.458   1.06   0.85--1.33   0.612   0.585
  rs2967605                                     33   19    8469738    intergenic      *RAB11B*       \[A/G\]     25/207/446    0.19   24/214/468    0.19   0.789   1.08   0.86--1.35   0.526   0.717
  rs6511720                                     33   19   11202306     intronic        *LDLR*        \[T/G\]     11/145/526    0.12    6/144/558    0.11   0.313   1.08   0.82--1.43   0.575   0.083
  rs2228671                                     34   19   11210912     missense        *LDLR*        \[T/C\]     12/148/521    0.13    8/160/542    0.12   0.852   1.00   0.77--1.30   0.989   0.289
  [4](#nt113){ref-type="table-fn"}rs10401969    32   19   19407718     intronic       *SUGP1*        \[C/T\]      5/91/587     0.07    4/101/605    0.08   0.778   0.93   0.67--1.29   0.667   0.415
  [5](#nt114){ref-type="table-fn"}rs17216525    32   19   19662220    intergenic    *CILP2PBX4*      \[T/C\]      5/97/582     0.08    6/107/597    0.08   0.589   0.94   0.68--1.29   0.685   0.382
  rs2304130                                     34   19   19789528     intronic       *ZNF101*       \[G/A\]      7/96/571     0.08    5/106/594    0.08   0.949   0.98   0.72--1.34   0.913   0.487
  rs157580                                      34   19   45395266     intronic       *TOMM40*       \[G/A\]     122/319/242   0.41   121/345/241   0.42   0.873   1.01   0.84--1.21   0.916   0.626
  rs2075650                                     34   19   45395619     intronic       *TOMM40*       \[G/A\]     11/163/508    0.14   10/184/514    0.14   0.522   1.01   0.78--1.30   0.956   0.877
  rs439401                                      34   19   45414451    intergenic    *APOE/APOC1*     \[T/C\]     96/313/275    0.37   96/348/266    0.38   0.544   0.99   0.82--1.18   0.882   0.772
  rs4420638                                     33   19   45422946    intergenic      *APOC1*        \[G/A\]     24/224/421    0.20   11/199/475    0.16   0.005   1.51   1.19--1.91   0.001   0.0160
  rs6102059                                     33   20   39228784    intergenic       *MAFB*        \[T/C\]     68/312/304    0.33   65/327/318    0.32   0.750   0.96   0.80--1.17   0.713   0.499
  rs7679                                        33   20   44576502      3′UTR         *PCIF1*        \[C/T\]     29/178/473    0.17   24/222/462    0.19   0.242   0.91   0.72--1.14   0.389   0.027

Minor alleles are presented first followed by major allele.

Unadjusted P values were calculated as tests for trend (1 df) across genotypes.

Odds ratios and 95% confidence intervals are calculated on a per allele basis for the minor allele assuming an additive model.

Adjusted P values were calculated as tests for trend (1 df) across genotypes in a logistic regression which included terms for collection center, gender, duration of T1DM and HbA1c category. Associations were no longer significant after correction for multiple testing performed by permutation test (n = 100,000).

In a sensitivity analysis (Control samples only with eGFR\>60 ml/min/1.73 m^2^; n = 444) adjusted P values were calculated as tests for trend (1 df) across genotypes in a logistic regression which included terms for collection center, gender, duration of T1DM and HbA1c category. Associations were no longer significant after correction for multiple testing performed by permutation test (n = 100,000).

Proxy for rs599839 (r^2^ = 0.90).

Proxy for rs17145738 (r^2^ = 1).

Proxy for rs17321515 (r^2^ = 0.97).

Proxy for rs16996148 (r^2^ = 0.90).

Proxy for rs16996148 (r^2^ = 1).

Single marker testing stratified by collection center identified two non-coding SNPs (rs1532624 in Cholesteryl ester transfer protein (*CETP*) and rs4420638 in Apolipoprotein C-I *APOC1*) to be significantly associated with DN ([Table 2](#pone-0058472-t002){ref-type="table"}). In logistic regression analysis with adjustment by collection center, gender, duration of T1D, and average HbA1c as covariates, the significance of both SNPs was maintained (rs1532624: odds ratio \[OR\]  = 0.82; confidence intervals \[CI\]: 0.69--0.99; P = 0.034; rs4420638: OR = 1.51; CI: 1.19--1.91; P = 0.001). The sensitivity analysis (that includes samples only from those controls with eGFR \>60 ml/min/1.73 m^2^) identified two SNPs significantly associated with DN in the fully adjusted model (rs4420638; P = 0.016 and rs7679; P = 0.027). However, no associations were maintained following correction for multiple testing. Subgroup analyses showed no association of any SNP with ESRD status.

With no prior hypotheses or supporting evidence of potential gene-gene interaction, we assumed a more stringent level of significance (P\<0.01). Interactions were assessed using likelihood ratio χ^2^ tests in the logistic regression with terms for potential confounders (collection center, gender, duration of T1D and HbA1c) included in the model. Seven interaction terms exceeded the minimum threshold set but following correction for multiple testing and examination of the resultant Q-Q plot, none were identified as being worthy of further investigation ([Table 3](#pone-0058472-t003){ref-type="table"}).

10.1371/journal.pone.0058472.t003

###### Assessment of gene-gene pair-wise interactions.

![](pone.0058472.t003){#pone-0058472-t003-3}

  SNP 1          Gene 1      SNP 2        Gene 2      ^1^P value   ^2^P value
  ------------ ---------- ------------ ------------- ------------ ------------
  rs3905000     *ABCA1*      rs7679       *PCIF1*       0.002        0.014
  rs6756629     *ABCG5*     rs714052      *BAZ1B*       0.003        0.009
  rs2240466     *BAZ1B*    rs6756629      *ABCG5*       0.007         0.01
  rs2240466     *BAZ1B*    rs12678919      *LPL*        0.007        0.115
  rs1167998     *DOCK7*    rs17216525   *CILP2PBX4*     0.008        0.002
  rs10903129    *TMEM57*   rs6544713      *ABCG8*       0.009        0.024
  rs12678919     *LPL*      rs714052      *BAZ1B*       0.009         0.14

The number of significant interactions observed is less than one might expect by chance.

P values for gene-gene interactions were obtained between SNPs using likelihood ratio χ^2^ tests in the logistic regression. Data are presented for those which attained significance at the P\<0.01 level in an unadjusted model^1^. Significance levels are also presented where terms for potential confounders (collection center, gender, duration of T1D and HbA1c) are included in the adjusted model^2^.

Discussion {#s4}
==========

Dyslipidemia can result through dietary and lifestyle influences or alternatively as a consequence of variation in genes pivotal to lipoprotein metabolism. In persons with diabetes, prolonged elevation of insulin levels often leads to dyslipidemia, a process central to the pathogenesis of atherosclerosis and increasing CVD risk. As previous studies have reported multiple lipid abnormalities in patients with T1D [@pone.0058472-Groop1]--[@pone.0058472-Tolonen1], we evaluated common polymorphic variation previously associated with dyslipidemia, in persons with T1D, both with and without DN. Univariate analysis identified two SNPs associated with DN (rs1532624 in *CETP* and rs4420638 in *APOC1*) both of which remained significant following adjustment for collection center, gender, duration of T1D, and average HbA1c. Interestingly, rs4420638 was also significantly associated with DN in the sensitivity analysis using only those samples from diabetic controls with eGFR \>60 ml/min/1.73 m^2^. However, following correction for multiple testing, these associations were no longer significant. Although, published data were available from the US GoKinD genome-wide association study, limited coverage on the Affymetrix 500 K genotyping platform across the genomic locations of both *CETP* and *APOC1*, prevented *in silico* independent replication or meta-analysis of our top SNPs or any potential proxies (r^2^\>0.8) [@pone.0058472-Pezzolesi1].

In previously published studies the definition of the DN phenotype has proved challenging. We do not think it is surprising that cases in our study had persistent proteinuria (macroalbuminuria) despite the use of antihypertensive medication. The use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), typically reduces but does not abolish protein excretion in persons with overt diabetic nephropathy [@pone.0058472-Lewis1]--[@pone.0058472-Brenner1] suggesting that persistent proteinuria is unlikely to be a consequence of suboptimal blood pressure control. The differences in mean blood pressures observed between case and control groups were consistent with findings in clinical practice.

In addition, it has been suggested that some individuals with a very prolonged duration of type 1 diabetes may develop chronic kidney disease (CKD) without albuminuria. Molitch and colleagues [@pone.0058472-Molitch2] identified 89 of the 1,439 individuals recruited to the DCCT/EDIC study that had developed CKD (defined by estimated GFR \<60 ml/min/1.73 m^2^) after almost 20 years of follow up. Of the 89 individuals with CKD, 21 were classified as normoalbuminuric (albumin excretion rate \[AER\] \<30); 14 as microalbuminuric (AER: 30--300); and 54 as macroalbuminuric (AER \>300). Of note 43% of the normoalbuminuric individuals with CKD were taking ACEi during the study and 14% were taking ARBs at year 13/14 of the EDIC study [@pone.0058472-Molitch2]. The antihypertensive drugs, ACEi and ARBs, can both lower AER and reduce eGFR which may partly explain why the authors found a small number of individuals with normoalbuminuria and reduced eGFR. The normoalbuminuric patients with reduced eGFR were also 4 years older at time of recruitment than the macroalbuminuric patients (30+/−7 yr vs. 26+/− 7 yr [@pone.0058472-Molitch2]). Nevertheless, we did attempt to address this issue of diabetic patients having CKD without albuminuria. In a sensitivity analysis, we excluded all those diabetic patients we had originally recruited as normalbuminuric controls in whom the eGFR was \<60 ml/min/1.73 m^2^. We excluded these controls with reduced renal function from our analysis to limit any risk of misclassification of nephropathy status but found this made little difference to the main analysis ([Table 2](#pone-0058472-t002){ref-type="table"}).

CETP is a protein central to the process of dyslipidemia. It acts as a mediator for the transfer of cholesteryl esters from HDL to VLDL or LDL in exchange for triglycerides, reducing serum HDL concentrations [@pone.0058472-Lagrost1]. Variation in CETP levels have been correlated with lipid metabolism and insulin resistance in Type 2 diabetes [@pone.0058472-Weitgasser1], and also in association with the development of obesity [@pone.0058472-TernGarca1] and susceptibility to atherosclerosis and other CVD [@pone.0058472-Dullaart1]. Recently, Igl and colleagues demonstrated that the genetic influence mediated by rs1532624 could be attenuated by lifestyle factors such as diet or physical activity, highlighting the potential for interaction at this locus [@pone.0058472-Igl1]. Our study was unable to examine lifestyle influences, as dietary and physical activity measurements were not collected during recruitment. Nonetheless we sought to evaluate the potential for pair-wise gene-gene interaction between the candidate SNPs examined. Several pair-wise interactions which included the *CETP* and *APOB* loci were identified but did not remain significant following correction for multiple testing. As no association survived correction for multiple testing, it is unlikely these gene variants play a specific role in the etiology of DN.

Apo C-I is a protein constituent of chylomicrons, VLDL and HDL and while its precise physiological role is not well established, evidence has demonstrated support for its involvement in HDL metabolism through activation and inhibition of other proteins central to lipid metabolism, including CETP [@pone.0058472-Lahiry1]. Association of rs4420638 with DN in T1D in this cohort has been previously reported [@pone.0058472-McKnight1].

Improved therapeutic regimens to lower LDL levels using statins have proved beneficial for patients both with and without diabetes with respect to CVD risk. In addition, increasing evidence suggests statins provide therapeutic benefit independent of cholesterol modulation, by improving endothelial and vascular function and reducing inflammation [@pone.0058472-Danesh1].

Common genetic loci explain only a proportion of the variation observed in lipid levels within the general population. Evidence in support of rare variants with potentially large individual effect size continues to grow, and is likely to make a significant impact on the genetic heritability of this condition [@pone.0058472-Johansen1]. Since our study focused only on common variants, untyped, highly penetrant rare variants in these genes could also contribute to DN. This study has insufficient power to detect rare variants particularly if the effect sizes are small in magnitude, such as the odds ratios of 1.2/1.3 which are more commonly found in common complex diseases ([Table 4](#pone-0058472-t004){ref-type="table"}). Future amalgamation of independent cohorts with similar DN phenotypes will enable a more robust evaluation of such loci. In addition, other factors such as copy number variation or indeed epigenetic mechanisms (e.g. DNA methylation, histone modification and microRNAs) may also attenuate gene function affecting these pathways which modulate disease risk.

10.1371/journal.pone.0058472.t004

###### Study power to detect various odds ratios for selected minor allele frequencies.

![](pone.0058472.t004){#pone-0058472-t004-4}

  Odds    Minor Allele Frequency (MAF)               
  ------ ------------------------------ ----- ------ ------
  1.2                 30%                49%   59%    65%
  1.3                 56%                81%   89%    92%
  1.4                 79%                96%   99%    99%
  1.5                 93%                99%   100%   100%

Power calculations are based on 684 cases and 710 controls with odds ratio ranging from 1.2--1.5 for SNPs with a MAF between 0.10 and 0.40 with no correction for multiple testing.

Although the SNPs assessed in this study were chosen on the basis of previous associations with dyslipdemia there are a number of inherent limitations associated with using 53 SNPs across 37 genes [@pone.0058472-Cardon1]: (1) identification of association does not necessarily equate to functional significance given the concept of linkage disequilibrium (LD). (2) assessing one or two SNPs per gene may provide inadequate representation of the genetic architecture at that locus. (3) patterns of LD can vary significantly within and between different populations and therefore a significant association in one population may not necessarily translate across all populations.

In conclusion, we found no strong association between common variants in genes involved in dyslipidemia and DN. Further work to investigate lifestyle factors which influence genes may identify potential risk factors for susceptibility to DN.
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